CALCA and migraine disorder: Whereas more recent research has focussed on monoclonal antibodies targeting either CGRP or its receptor (reviewed elsewhere in this special issue) for the prophylactic treatment of migraine [54, 55], the current review will focus on the development of the “gepant” class of compounds for acute migraine therapy.